Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
…, M Esen, C Horn, S Eberts, A Kroidl… - The Lancet Infectious …, 2022 - thelancet.com
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study
…, D Kowour, G Rojas-Ponce, A Kroidl… - Clinical infectious …, 2012 - academic.oup.com
Background. Diagnosis and timely treatment of tuberculosis in children is hampered by the
absence of fast and reliable tests, especially in the era of human immunodeficiency virus (HIV…
absence of fast and reliable tests, especially in the era of human immunodeficiency virus (HIV…
[HTML][HTML] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
PG Kremsner, P Mann, A Kroidl, I Leroux-Roels… - Wiener Klinische …, 2021 - Springer
Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers
…, J Bosch, R Fendel, JJ Gabor, A Kreidenweiss, A Kroidl… - MedRxiv, 2020 - medrxiv.org
There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)
…, L Maboko, F Sawe, MS Schunk, A Kroidl… - The Journal of …, 2010 - academic.oup.com
Background. Human immunodeficiency virus (HIV) vaccine development remains a global
priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a …
priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a …
Retention in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV‐positive women …
…, HD Meriki, M Hoelscher, A Kroidl - Tropical Medicine & …, 2017 - Wiley Online Library
Objective To assess linkage and retention in care along the PMTCT cascade in HIV ‐positive
pregnant and breastfeeding women initiating Option B+ in Cameroon. Methods We …
pregnant and breastfeeding women initiating Option B+ in Cameroon. Methods We …
[HTML][HTML] Seroepidemiology and model-based prediction of SARS-CoV-2 in Ethiopia: longitudinal cohort study among front-line hospital workers and communities
…, J Hasenauer, A Wieser, A Kroidl - The Lancet Global …, 2021 - thelancet.com
Background Over 1 year since the first reported case, the true COVID-19 burden in Ethiopia
remains unknown due to insufficient surveillance. We aimed to investigate the …
remains unknown due to insufficient surveillance. We aimed to investigate the …
[HTML][HTML] Dynamics and durability of HIV-1 neutralization are determined by viral replication
…, C Geldmacher, O Geisenberger, A Kroidl… - Nature Medicine, 2023 - nature.com
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent
infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet …
infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet …
[HTML][HTML] Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a …
PJ Munseri, A Kroidl, C Nilsson, A Joachim… - PloS one, 2015 - journals.plos.org
Background Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting
induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 …
induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 …
Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania
We evaluated the diagnostic performance of two tests based on the release of
lipoarabinomannan (LAM) into the urine, the MTB-LAM-ELISA assay and the Determine TB-LAM-strip …
lipoarabinomannan (LAM) into the urine, the MTB-LAM-ELISA assay and the Determine TB-LAM-strip …